Why is Vivimed Labs Ltd falling/rising?

As of 14-Aug, Vivimed Labs Ltd's stock price is falling, currently at Rs 4.93, which reflects a decrease of Rs 0.06 or 1.2%. The stock has been underperforming significantly, with a decline of 2.57% over the past week and a substantial drop of 7.16% over the past month. Year-to-date, the stock has plummeted by 72.04%, while the benchmark Sensex has only fallen by 8.46% during the same period.The stock is currently trading close to its 52-week low, being only 3.45% away from Rs 4.76. Additionally, it has been on a downward trend, experiencing consecutive falls for the last three days, resulting in a total decline of 4.46% in that timeframe. Vivimed Labs Ltd is also trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a persistent bearish trend.Investor participation has decreased significantly, with delivery volume dropping by 77.63% compared to the 5-day average, suggesting a lack of interest from investors. Overall, these factors contribute to the stock's decline, reflecting a challenging performance relative to both its historical performance and the broader market.

Which are the latest news on Vivimed Labs.?

Vivimed Labs Ltd is Rated Strong Sell Vivimed Labs Ltd Locks at Upper Circuit With 4.92% Gain — Buyers Queue, Sellers Absent

Who are in the management team of Vivimed Labs.?

The management team of Vivimed Labs includes the following individuals:1. **Santosh Varalwar** - Managing Director2. **V Manohar Rao** - Whole Time Director3. **Subhash Varalwar** - Non Executive Director4. **Sandeep Varalwar** - Whole Time Director5. **S Raghunandan** - Whole Time Director6. **M Bhagvanth Rao** - Non Executive Independent Director7. **Nixon Patel** - Non Executive Independent Director8. **Umanath Varahabhotla** - Non Executive Independent Director9. **Yugandhar Kopparthi** - Company Secretary & Compliance OfficerThis team plays a crucial role in guiding the company's strategic direction and operations.

What does Vivimed Labs. do?

Overview: Vivimed Labs Ltd is engaged in the manufacturing of specialty chemicals primarily for the personal care and cosmetic industry, as well as pharmaceuticals, APIs, and formulations, operating within the pharmaceuticals and drugs industry in the micro-cap market.History: Vivimed Labs Ltd was incorporated in an unspecified year and has undergone various status changes. The latest quarterly results reported net sales and net profit for the period ending March 2026.Financial Snapshot: Most recent Net Sales: 12 Cr (Quarterly Results - Mar 2026) Most recent Net Profit: -147 Cr (Quarterly Results - Mar 2026) Market-cap value: INR 42 Cr (Micro Cap)Key Metrics: P/E: N/A Industry P/E: 37 Dividend Yield: 0.00% Debt-Equity: -1.88 Return on Equity: 83.86% Price-to-Book: -0.20 Contact Details: Address: Plot No 78-A, Kolhar Industrial Area Bidar Karnataka : 585403 Phone: 91-8482-232045 Email: yugandhar.kopparthi@vivimedlabs.com Website: http://www.vivimedlabs.com

Who are the peers of the Vivimed Labs.?

Peers: The peers of Vivimed Labs. are Sun Pharma.Inds., Divi's Lab., Torrent Pharma, Cipla, Dr Reddy's Labs, ANG Lifesciences, Deccan Healthcar, Unick Fix-A-Form, and Parabolic Drugs.Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Torrent Pharma, Cipla, and Dr Reddy's Labs, while Below Average management risk is found at Vivimed Labs., ANG Lifesciences, Deccan Healthcar, and Unick Fix-A-Form. Growth is Excellent at Sun Pharma.Inds., Good at Deccan Healthcar, Average at Torrent Pharma and Dr Reddy's Labs, and Below Average at Divi's Lab., Cipla, Vivimed Labs., ANG Lifesciences, Unick Fix-A-Form, and the rest. Capital Structure is Excellent at Sun Pharma.Inds., Divi's Lab., and Cipla, Good at Torrent Pharma and Deccan Healthcar, while Below Average is noted for Vivimed Labs., ANG Lifesciences, Unick Fix-A-Form, and Parabolic Drugs.Return Snapshot: The peer with the highest 1-year return is Guj. Inject(Ker) at 469.95%, while Vivimed Labs. has a 1-year return that is not available. In comparison, ANG Lifesciences has a 1-year return of 8.80%. Additionally, Deccan Healthcar and Unick Fix-A-Form have negative six-month returns.

VIVIMEDLAB Share Price | Vivimed Labs Ltd Stock Analysis & Recommendation

Key Events This Week

Aug 10: New 52-week low of Rs.4.83

Aug 11: All-time low reached at Rs.4.76 and upper circuit hit at Rs.5.12

Aug 12: Stock declined to Rs.5.07 amid heavy volume

Aug 13: Further dip to Rs.4.99 on low volume

Aug 14: Week closes at Rs.4.93 (-1.20%)

Week Open

Rs.5.06

Read full news article

Vivimed Labs Ltd is Rated Strong Sell

Vivimed Labs Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 May 2026, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 12 August 2026, providing investors with the latest data to understand the rationale behind this rating.

Read full news article

Vivimed Labs Ltd Locks at Upper Circuit With 4.92% Gain — Buyers Queue, Sellers Absent

At Rs 5.12, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Vivimed Labs Ltd locked at its upper circuit of 4.92% on 11 Aug 2026, with buyers queuing and no sellers willing to part with shares.

Read full news article

[ { "link": "quarterly", "btn_text": "All Quarterly Results", "header": "Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ", "rhs": [ { "prefix": "Net Sales ", "suffix": "QoQ Growth in quarter ended Mar 2026 is -35.08% vs -48.49% in Dec 2025", "dir": 1 }, { "prefix": "Standalone Net Profit ", "suffix": "QoQ Growth in quarter ended Mar 2026 is -757.57% vs -274.89% in Dec 2025", "dir": -1 } ], "table": { "header": [ "Mar'26", "Dec'25", "Change(%)" ], "body": [ { "field": "Net Sales", "val1": "7.55", "val2": "11.63", "chgp": "-35.08%", "chgp_class": "negative" }, { "field": "Operating Profit (PBDIT) excl Other Income", "val1": "-137.01", "val2": "-11.22", "chgp": "-1,121.12%", "chgp_class": "negative" }, { "field": "Interest", "val1": "0.79", "val2": "0.94", "chgp": "-15.96%", "chgp_class": "positive" }, { "field": "Exceptional Items", "val1": "0.00", "val2": "0.00", "chgp": "", "chgp_class": "neutral" }, { "field": "Standalone Net Profit", "val1": "-142.10", "val2": "-16.57", "chgp": "-757.57%", "chgp_class": "negative" }, { "field": "Operating Profit Margin (Excl OI)", "val1": "-1,814.70%", "val2": "-96.47%", "chgp": "-1,718.23%", "chgp_class": "negative" } ] } }, { "link": "half-yearly", "btn_text": "All Half Yearly Results", "header": "Half Yearly Results Snapshot (Consolidated) - Sep'22", "rhs": [ { "prefix": "Net Sales ", "suffix": " Growth in half year ended Sep 2022 is -21.15% vs -78.03% in Sep 2021", "dir": 1 }, { "prefix": "Consolidated Net Profit ", "suffix": " Growth in half year ended Sep 2022 is -72.57% vs -3,185.90% in Sep 2021", "dir": 1 } ], "table": { "header": [ "Sep'22", "Sep'21", "Change(%)" ], "body": [ { "field": "Net Sales", "val1": "94.33", "val2": "119.63", "chgp": "-21.15%", "chgp_class": "negative" }, { "field": "Operating Profit (PBDIT) excl Other Income", "val1": "-17.88", "val2": "0.31", "chgp": "-5,867.74%", "chgp_class": "negative" }, { "field": "Interest", "val1": "18.17", "val2": "18.12", "chgp": "0.28%", "chgp_class": "negative" }, { "field": "Exceptional Items", "val1": "0.00", "val2": "0.00", "chgp": "", "chgp_class": "neutral" }, { "field": "Consolidate Net Profit", "val1": "-44.23", "val2": "-25.63", "chgp": "-72.57%", "chgp_class": "negative" }, { "field": "Operating Profit Margin (Excl OI)", "val1": "-18.95%", "val2": "0.26%", "chgp": "-19.21%", "chgp_class": "negative" } ] } }, { "link": "nine-monthly", "btn_text": "All Nine Monthly Results", "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'22", "rhs": [ { "prefix": "Net Sales ", "suffix": "YoY Growth in nine months ended Dec 2022 is -14.81% vs -78.58% in Dec 2021", "dir": 1 }, { "prefix": "Consolidated Net Profit ", "suffix": "YoY Growth in nine months ended Dec 2022 is -26.83% vs 2.03% in Dec 2021", "dir": -1 } ], "table": { "header": [ "Dec'22", "Dec'21", "Change(%)" ], "body": [ { "field": "Net Sales", "val1": "150.07", "val2": "176.15", "chgp": "-14.81%", "chgp_class": "negative" }, { "field": "Operating Profit (PBDIT) excl Other Income", "val1": "-23.01", "val2": "-6.98", "chgp": "-229.66%", "chgp_class": "negative" }, { "field": "Interest", "val1": "27.39", "val2": "29.70", "chgp": "-7.78%", "chgp_class": "positive" }, { "field": "Exceptional Items", "val1": "0.00", "val2": "0.00", "chgp": "", "chgp_class": "neutral" }, { "field": "Consolidate Net Profit", "val1": "-62.54", "val2": "-49.31", "chgp": "-26.83%", "chgp_class": "negative" }, { "field": "Operating Profit Margin (Excl OI)", "val1": "-15.33%", "val2": "-3.96%", "chgp": "-11.37%", "chgp_class": "negative" } ] } }, { "link": "annual", "btn_text": "All Annual Results", "header": "Annual Results Snapshot (Consolidated) - Mar'26", "rhs": [ { "prefix": "Net Sales ", "suffix": "YoY Growth in year ended Mar 2026 is -39.80% vs -37.86% in Mar 2025", "dir": -1 }, { "prefix": "Consolidated Net Profit ", "suffix": "YoY Growth in year ended Mar 2026 is -452.16% vs 90.27% in Mar 2025", "dir": -1 } ], "table": { "header": [ "Mar'26", "Mar'25", "Change(%)" ], "body": [ { "field": "Net Sales", "val1": "69.99", "val2": "116.27", "chgp": "-39.80%", "chgp_class": "negative" }, { "field": "Operating Profit (PBDIT) excl Other Income", "val1": "-152.43", "val2": "-13.05", "chgp": "-1,068.05%", "chgp_class": "negative" }, { "field": "Interest", "val1": "4.17", "val2": "2.95", "chgp": "41.36%", "chgp_class": "negative" }, { "field": "Exceptional Items", "val1": "0.00", "val2": "0.00", "chgp": "", "chgp_class": "neutral" }, { "field": "Consolidate Net Profit", "val1": "-176.47", "val2": "-31.96", "chgp": "-452.16%", "chgp_class": "negative" }, { "field": "Operating Profit Margin (Excl OI)", "val1": "-217.79%", "val2": "-11.22%", "chgp": "-206.57%", "chgp_class": "negative" } ] } } ]